Astellas invests in new company focused on diabetes and celiac disease
This article was originally published in Scrip
Executive Summary
Astellas Pharma and Anokion have agreed to collaborate in the fields of type 1 diabetes and celiac disease. A new company, Kanyos Bio, has been created to develop clinical candidates in the two selected indications, with an option for Astellas to add a third autoimmune indication as part of the collaboration.